Impact of Pre-existing NS5A-L31 or -Y93H Minor Variants on Response Rates in Patients Infected with HCV Genotype-1b Treated with Daclatasvir/Asunaprevir
Crossref DOI link: https://doi.org/10.1007/s12325-016-0354-1
Published Online: 2016-06-10
Published Print: 2016-07
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Hernandez, Dennis
Yu, Fei
Huang, Xin
Kirov, Stefan
Pant, Saumya
McPhee, Fiona
Funding for this research was provided by:
Bristol-Myers Squibb
License valid from 2016-06-10